FOR IMMEDIATE RELEASE
David W. Moskowitz MD
Director, Field Operations
Legislative District 58
Missouri House of Representatives
The Honorable Jeanette Oxford
Representative, District 59
Missouri House of Representatives
ST. LOUIS—July 20, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today with pride that the Honorable Jeanette Mott Oxford and the Honorable James Morris have endorsed its campaign to make their districts at least 90% free of kidney disease by 2014.
GenoMed published in 2002 how to reverse early-stage kidney failure in patients with type 2 diabetes or high blood pressure. These two diseases cause over 90% of kidney failure that requires dialysis with the kidney machine.
Both Rep. Oxford’s district in south St. Louis and Rep. Morris’s district in north St. Louis each contain about 35,000 people. Their districts are among the oldest, most population-dense, and most ethnically and economically diverse districts in the state, including significant numbers of families living in poverty.
David W. Moskowitz, MD FACP, GenoMed’s CEO and Chief Medical Officer, said “Education is the key to eliminating 90% of new cases of kidney failure. We’ll be working with primary care providers and pharmacists in Districts 58 and 59 to identify and treat patients with diabetes and high blood pressure. We’ll adjust their medications intensively over a period of 2 to 3 months. By the end of 2010, we hope to have covered every patient in both Districts.”
Dr. Moskowitz added, “The drugs we use are generic and cheap. GenoMed’s fees are low enough for everybody in these Districts to afford. Preventive molecular medicine is actually quite inexpensive, about 100 times cheaper than dialysis.”
Dr. Moskowitz ended by saying, “I’m thrilled that Rep. Oxford and Rep. Morris are courageously leading their Districts to better public health. They live Missouri’s motto, Salus populi suprema lex esto [“Let the health of the people be the supreme law”]. Their Districts are lucky to have them.”
GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. As the only Public Health Company™, GenoMed aims to arrest diabetes, hypertension, and emphysema everywhere. Please contact Dr. Moskowitz if you have one of these diseases.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.